CD274 and bladder transitional cell carcinoma: The recent approval of immune checkpoint inhibitors, particularly the anti-PD1/PDL1 reagent, has revolutionized BLCA treatment by demonstrating prolonged response duration and clinical benefits in BLCA cases [7].